Latest News

Latest news is provided by our trusted partners at MJH Life Sciences® and its brands, and is not a publication of TACOS.

Consensus Recommendations Address Key Controversies in Lymphoma Management

May 13, 2026

Chris Ryan

Alexey Danilov, MD, PhD, and Tycel Phillips, MD, highlight key consensus viewpoints in lymphoma published from the 2025 Bridging the Gaps meeting.

UCSF Receives Major Gift to Advance Research and Modernization

May 13, 2026

UCSF Health

Kathy Chiao and Ken Hao commit $100 million for major capital projects, cancer research, and innovation at UCSF — building on a recent $75 million gift to UC Davis for veterinary medicine.

AUA and SUO Amend Advanced Prostate Cancer Guideline

May 12, 2026

Kyle Doherty

The AUA and SUO released the 2026 amendment to the Advanced Prostate Cancer Guideline.

Temple Health’s Fox Chase Cancer Center and Labcorp Collaborate to Test Ultra-Sensitive Blood-Based Assay for Early-Stage Lung Cancer Recurrence Risk

May 12, 2026

Fox Chase Cancer Center

A Fox Chase Cancer Center study will evaluate a tumor-informed, whole-genome sequencing–based test to assess recurrence risk in early-stage NSCLC.

FDA Grants Breakthrough Therapy Designation to Emi-Le for Adenoid Cystic Carcinoma

May 12, 2026

Ashling Wahner

Emi-Le received breakthrough therapy designation from the FDA for the treatment of patients with locally advanced, recurrent or metastatic ACC.

[177Lu]Lu-D-Dan-Phe-PSMA Demonstrates Manageable Safety and Early Efficacy mCRPC

May 12, 2026

Kyle Doherty

[177Lu]Lu-D-Dan-Phe-PSMA showed early signals of safety and activity in mCRPC.

FDA Issues Warning Regarding Risk of Secondary Primary Malignancies With Tazemetostat in Follicular Lymphoma, Epithelioid Sarcoma

May 12, 2026

Chris Ryan

The FDA issued a warning about the risk of secondary primary malignancies associated with tazemetostat in epithelioid sarcoma and follicular lymphoma.

GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026

May 12, 2026

Kyle Doherty

We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.

Real-World Data Highlight Survival Benefit of Rituximab Maintenance After Frontline BR in MCL

May 11, 2026

Riley Kandel

Rituximab following first-line bendamustine demonstrated significant OS and EFS real-world benefits in mantle cell lymphoma.

Retrospective Data Show Potential Real-World TTNT and OS Improvements With Next-Generation BTK Inhibitors in R/R MCL

May 11, 2026

Chris Ryan

Retrospective data showed zanubrutinib was associated with improved real-world overall survival vs ibrutinib in second- or third-line mantle cell lymphoma.

MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors

May 11, 2026

Roswell Park Comprehensive Cancer Center

Roswell Park Comprehensive Cancer Center launched a phase 2 trial evaluating SurVaxM plus temozolomide in progressing neuroendocrine tumors.

INBRX-106 Plus Pembrolizumab Yields Efficacy Benefit vs Pembrolizumab Alone in First-Line HNSCC

May 11, 2026

Ashling Wahner

First-line INBRX-106 plus pembrolizumab generated a higher ORR vs pembrolizumab monotherapy in PD-L1–positive metastatic or unresectable HNSCC.

Treatment Intensification Gains Momentum in mCSPC Management

May 11, 2026

Kyle Doherty

During a recent OncLive Peer Exchange, prostate cancer experts discussed the evolving role of treatment intensification in mCSPC.

FDA Approval of Brexu-Cel for R/R MCL Calls for Raised Awareness of CAR T-Cell Therapy Safety Considerations

May 11, 2026

Riley Kandel

Luhua (Michael) Wang, MD, discusses the FDA approval of brexu-cel in mantle cell lymphoma and what to know about CAR T-cell therapy in clinical practice.

Nivolumab Plus SOC Therapy Shows Encouraging Disease Control in Grade Group 5 Prostate Cancer

May 10, 2026

Kyle Doherty

The regimen produced a 2-year freedom from biochemical recurrence rate of 90.3% in grade group 5 prostate cancer.